Gangagen Biotechnologies Pvt Ltd, Raghavendra Layout, Tumkur Road, Yeshwantpur, Bangalore 560022, India.
BMC Microbiol. 2011 Oct 11;11:226. doi: 10.1186/1471-2180-11-226.
Staphylococcus aureus is a major cause of nosocomial and community-acquired infections. However, the rapid emergence of antibiotic resistance limits the choice of therapeutic options for treating infections caused by this organism. Muralytic enzymes from bacteriophages have recently gained attention for their potential as antibacterial agents against antibiotic-resistant gram-positive organisms. Phage K is a polyvalent virulent phage of the Myoviridae family that is active against many Staphylococcus species.
We identified a phage K gene, designated orf56, as encoding the phage tail-associated muralytic enzyme (TAME). The gene product (ORF56) contains a C-terminal domain corresponding to cysteine, histidine-dependent amidohydrolase/peptidase (CHAP), which demonstrated muralytic activity on a staphylococcal cell wall substrate and was lethal to S. aureus cells. We constructed N-terminal truncated forms of ORF56 and arrived at a 16-kDa protein (Lys16) that retained antistaphylococcal activity. We then generated a chimeric gene construct encoding Lys16 and a staphylococcal cell wall-binding SH3b domain. This chimeric protein (P128) showed potent antistaphylococcal activity on global clinical isolates of S. aureus including methicillin-resistant strains. In addition, P128 was effective in decolonizing rat nares of S. aureus USA300 in an experimental model.
We identified a phage K gene that encodes a protein associated with the phage tail structure. The muralytic activity of the phage K TAME was localized to the C-terminal CHAP domain. This potent antistaphylococcal TAME was combined with an efficient Staphylococcus-specific cell-wall targeting domain SH3b, resulting in the chimeric protein P128. This protein shows bactericidal activity against globally prevalent antibiotic resistant clinical isolates of S. aureus and against the genus Staphylococcus in general. In vivo, P128 was efficacious against methicillin-resistant S. aureus in a rat nasal colonization model.
金黄色葡萄球菌是医院内和社区获得性感染的主要病因。然而,抗生素耐药性的迅速出现限制了治疗这种病原体引起的感染的治疗选择。噬菌体来源的溶壁酶最近因其作为针对抗生素耐药革兰阳性菌的抗菌剂的潜力而受到关注。噬菌体 K 是一种多价烈性噬菌体,属于肌尾噬菌体科,对许多葡萄球菌属具有活性。
我们鉴定了噬菌体 K 的一个基因,命名为 orf56,其编码噬菌体尾部相关的溶壁酶(TAME)。该基因产物(ORF56)包含一个对应于半胱氨酸、组氨酸依赖性酰胺水解酶/肽酶(CHAP)的 C 末端结构域,该结构域在葡萄球菌细胞壁底物上具有溶壁活性,对金黄色葡萄球菌细胞具有致死性。我们构建了 ORF56 的 N 端截断形式,并得到保留抗金黄色葡萄球菌活性的 16kDa 蛋白(Lys16)。然后,我们生成了一个编码 Lys16 和金黄色葡萄球菌细胞壁结合 SH3b 结构域的嵌合基因构建体。该嵌合蛋白(P128)对包括耐甲氧西林金黄色葡萄球菌在内的全球临床分离株金黄色葡萄球菌具有强大的抗金黄色葡萄球菌活性。此外,P128 在金黄色葡萄球菌 USA300 的大鼠鼻腔定植的实验模型中具有有效性。
我们鉴定了一个编码与噬菌体尾部结构相关的蛋白的噬菌体 K 基因。噬菌体 K TAME 的溶壁活性定位于 C 末端 CHAP 结构域。这种有效的抗金黄色葡萄球菌 TAME 与高效的金黄色葡萄球菌细胞壁靶向结构域 SH3b 结合,产生了嵌合蛋白 P128。该蛋白对全球流行的抗生素耐药性临床分离株金黄色葡萄球菌以及整个葡萄球菌属均具有杀菌活性。在体内,P128 在大鼠鼻腔定植模型中对耐甲氧西林金黄色葡萄球菌有效。